Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Automatic Production of [18F]F-DOPA Using the Raytest SynChrom R&D Module.

Author information

Affiliations

  • 1. Department of Inorganic and Analytical Chemistry, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, ul. Jagiellonska 13-15, 85-067 Bydgoszcz, Poland.
      Authors
    • Waśniowski P 1, 2
    • Sobiak S 1
    (2 authors)
  • 2. Nuclear Medicine Department, Oncology Centre Professor Franciszek Łukaszczyk Memorial, dr I. Romanowskiej 2 Street, 85-796 Bydgoszcz, Poland.
      Authors
    • Waśniowski P 1, 2
    • Czuczejko J 2
    • Chuchra M 2
    • Wędrowski M 2
    • Małkowski B 2
    (5 authors)
  • 3. Department of Manufacturing Techniques, Bydgoszcz University of Science and Technology, ul. Kaliskiego 7, 85-796 Bydgoszcz, Poland.
      Authors
    • Marciniak D 3
    (1 author)

ORCIDs linked to this article

Pharmaceuticals (Basel, Switzerland), 22 Dec 2022, 16(1):10
https://doi.org/10.3390/ph16010010 PMID: 36678506 PMCID: PMC9865388

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Abstract 

[18F]F-DOPA is widely used in PET diagnostics. Diseases diagnosed with this tracer are schizophrenia, Parkinson's disease, gliomas, neuroendocrine tumors, pheochromocytomas, and pancreatic adenocarcinoma. It should be noted that the [18F]F-DOPA tracer has been known for over 30 years. However, the methods of radiosynthesis applied in the past did not allow its clinical use due to low efficiency and purity. Currently, in the market, one encounters different types of radiosynthesis using the fluorine 18F isotope and variants of the same method. The synthesis and its modifications were carried out using a Raytest Synchrom R&D module. The synthesis consists of the following steps: (a) binding of the fluoride anion 18F- on an anion exchange column; (b) elution with TBAHCO3-; (c) nucleophilic fluorination to the ABX 1336 precursor; (d) purification of the intermediate product on the C18ec column; (e) Baeyer-Villiger oxidation; (f) hydrolysis; and (gfinal purification of the crude product on a semipreparative column. The nucleophilic synthesis of [18F]F-DOPA was successfully performed in 120 min, using the ABX 1336 precursor on the Raytest SynChrom R&D module, with a radiochemical yield (RCY) of 15%, radiochemical purity (RCP) ≥ 97%, and enantiomeric purity (ee) ≥ 96%.

Free full text 

Logo of pharmaceuticalsLink to Publisher's site
Pharmaceuticals (Basel). 2023 Jan; 16(1): 10.
Published online 2022 Dec 22. https://doi.org/10.3390/ph16010010
PMCID: PMC9865388
PMID: 36678506

Automatic Production of [18F]F-DOPA Using the Raytest SynChrom R&D Module

Paweł Waśniowski, Conceptualization, Methodology, Software, Validation, Formal analysis, Investigation, Resources, Data curation, Writing – original draft, Writing – review & editing, Visualization, Supervision, Project administration, Funding acquisition,1,2,* Jolanta Czuczejko, Methodology, Validation, Investigation, Data curation, Writing – original draft, Writing – review & editing,2,3 Michał Chuchra, Validation, Data curation, Writing – original draft, Writing – review & editing,2 Mateusz Wędrowski, Formal analysis, Writing – original draft, Writing – review & editing, Visualization,2,4 Dawid Marciniak, Software, Validation,5 Stanisław Sobiak, Formal analysis, Resources, Supervision,1 and Bogdan Małkowski, Resources, Supervision, Funding acquisition2,4
Junbo Zhang, Academic Editor
Author information Article notes Copyright and License information Disclaimer

Associated Data

Data Availability Statement

Abstract

[18F]F-DOPA is widely used in PET diagnostics. Diseases diagnosed with this tracer are schizophrenia, Parkinson’s disease, gliomas, neuroendocrine tumors, pheochromocytomas, and pancreatic adenocarcinoma. It should be noted that the [18F]F-DOPA tracer has been known for over 30 years. However, the methods of radiosynthesis applied in the past did not allow its clinical use due to low efficiency and purity. Currently, in the market, one encounters different types of radiosynthesis using the fluorine 18F isotope and variants of the same method. The synthesis and its modifications were carried out using a Raytest Synchrom R&D module. The synthesis consists of the following steps: (a) binding of the fluoride anion 18F− on an anion exchange column; (b) elution with TBAHCO3−; (c) nucleophilic fluorination to the ABX 1336 precursor; (d) purification of the intermediate product on the C18ec column; (e) Baeyer–Villiger oxidation; (f) hydrolysis; and (gfinal purification of the crude product on a semipreparative column. The nucleophilic synthesis of [18F]F-DOPA was successfully performed in 120 min, using the ABX 1336 precursor on the Raytest SynChrom R&D module, with a radiochemical yield (RCY) of 15%, radiochemical purity (RCP) ≥ 97%, and enantiomeric purity (ee) ≥ 96%.

Keywords: [18F]F-DOPA, Raytest SynChrom R&D, radiosynthesis

1. Introduction

The 3,4-dihydroxy-L-phenylalanine ([18F]F-DOPA) analog, labeled with the fluorine 18F isotope, is a tracer used in the imaging of the integrity and function of the dopaminergic nigrostriatal system and neurodegenerative diseases such as Parkinson’s disease via Positron Emission Tomography fused with the Computed Tomography (PET/CT) technique [1,2,3]. This marker has also found applications in oncology, especially in the imaging of neuroendocrine tumors (NETs) [4,5,6] and neuroblastoma [7,8].

In the first clinical applications of [18F]F-DOPA, electrophilic methods began to be used with the carrier-added (CA) [18F]F2 form, using automated synthesis modules [9,10,11,12]. This method, however, presents certain limitations resulting from the restricted access of the centers to the production of [18F]F2 in the nuclear reaction 20Ne(d, α)18F, and the system of transporting this gas to the synthesizer. Other limitations include the low molar activity and low efficiency of [18F]F-DOPA synthesis [13].

Due to the clinical increase in the need for [18F]F-DOPA, several synthesis methods have been developed using the no-carrier-added (NCA) nucleophilic substitution of Fluoride ([18F]F−) via the 18O (p, n) 18F nuclear reaction, which solved the above-mentioned problems and allowed for the widespread application of the tracer [14,15,16,17].

The aim of this study was to adapt [18F]F-DOPA radiosynthesis using the Baeyer–Villiger oxidation method with the ABX 1336 precursor to the Raytest SynChrom R&D module.

2. Results and Discussion

2.1. Recovery of the 18F Isotope from the Ion Exchange Column

The first stage of the synthesis was the recovery of the fluoride isotope from the bed of the quaternary methyl ammonium (QMA) anion exchange column. Earlier work on the nucleophilic synthesis of [18F]F-DOPA reported that both the type and amount of the phase transition catalyst (PTC) have an influence on the formation of by-products, which lowers the yield of the reaction [16,18]. Based on these results, tetrabutylammonium hydrogen carbonate (TBAHCO3−) was selected as the PTC for the synthesis and a series of elutions of the fluoride 18F isotope was performed from the QMA column, using various amounts of TBAHCO3−. The residues of 18F fluoride were confirmed on a QMA column 12 h after elution. The actual amount of the 18F residue was then calculated using the half-life formula.

After elution, azeotropic distillation was carried out at 80 °C with an inert gas stream of 800 mbar. The solvent vapors were collected in a vacuum trap immersed in liquid nitrogen. The distillation was repeated twice in order to completely evaporate the water, reducing the reactivity of fluoride. The volume of acetonitrile added to the second azeotropic distillation was always 50 µL higher than the sum of the volumes of TBAHCO3− and acetonitrile (MeCN) that remained in the reactor after recovery of the fluoride isotope. The addition of more solvent in the second distillation allows the TBAF[18F] complex, remaining from the first azeotropic distillation, to be removed from the walls of the reactor.

The amount of TBAHCO3− and MeCN added during elution from the column influences the activity of 18F fluoride collected in the reaction vessel. It was noted that the residues of the 18F isotope, with an amount of 100–200 µL TBAHCO3−, are comparable. The addition of TBAHCO3− in an amount of 50 µL results in an average 18F fluoride residue of 10,700 MBq. In addition to the amount of 18F fluoride recovered, the influence of the time of the first and second azeotropic distillations on the decrease in its activity, caused by drying time, was considered. It was found that the greater amount of reagents added, the longer the evaporation time. Considering the above-mentioned factors, the total decrease in activity was calculated, resulting from the sum of the residual 18F fluoride on the column and the decrease in activity due to the time of azeotropic distillation, compared to the starting activity (120 GBq). The most preferable amount of TBAHCO3− and MeCN is 100 µL, as a result of the percentage point of activity decrease, which consists of the residual isotope on the ion exchange column and the duration of the azeotropic drying (Table 1).

Table 1

Effect of the PTC amount and azeotropic distillation time on the activity of the recovered fluoride isotope 18F.

Amount of TBAHCO3−
(µL)		Amount of MeCN (µL)Activity Remained on the Column 12 H after the End of the Synthesis (MBq)Calculated Remaining Activity (MBq)Total Drying Time after Two Azeotropic Distillations (Min)Percentage Activity Decrease (%)
50 µL50 µL1.20 MBq10,700 MBq8 min13.4%
100 µL100 µL0.45 MBq4000 MBq12 min10.4%
150 µL150 µL0.37 MBq3300 MBq16 min12.1%
200 µL200 µL0.25 MBq2300 MBq21 min14.1%
EOB = 120 GBq, 80 °C, n = 3

2.2. 18F Isotope Labeling of the Precursor

The next phase was to add the precursor dissolved in dimethylformamide (DMF) to the first reactor. Two commercially available amounts of the ABX precursor 1336 were compared, namely, 10 mg and 30 mg. The results are summarized in Table 2.

Table 2

Effect of the amount of the precursor on the labeling efficiency.

Amount of Precursor (mg)Amount of Solvent (µL)Time (min)RCY (%)
10 mg 500 µL10 min70%
30 mg1000 µL10 min10%
TBAHCO3−, DMF, 110 °C, n = 3

First, radiolabeling was performed with 10 mg of the precursor in 500 µL of DMF by adding it to the dried TBAF[18F] complex. Next, labeling was carried out at 110 °C for 10 min. The radiolabeling efficiency during the first syntheses reached RCY = 40–50%. However, in subsequent syntheses, fluctuations in the labeling efficiency were observed, which decreased to an RCY of 10%. It was noted that the color of the reaction mixture was red at high yields and black at low yields.

The reactor was dismantled to determine the cause of the labeling fluctuations. It turned out that the liquid remaining after the cleaning procedure was accumulating in the vessel to which the dissolved precursor was added, and under the reactor seal. Additionally, the cleaning procedure did not always clean the reactor, the reactor needle, and the magnetic stirrer of compound residues after radiolabeling (Figure 1a,b).

An external file that holds a picture, illustration, etc. Object name is pharmaceuticals-16-00010-g001.jpg

Uncleaned (a) reactor and (b) magnetic stirrer after the automatic cleaning procedure.

Initially, the procedure for cleaning and drying the synthesis module was extended, but an alternative and more practical solution was to replace the precursor and MeCN vessel with a disposable plastic syringe (Figure 2 and Figure 3). Furthermore, manual cleaning of the reactor, magnetic stirrer, needle, and reactor rubber was used. Under these conditions, labeling was performed, which was stable, averaging 68% (see Table 3).

An external file that holds a picture, illustration, etc. Object name is pharmaceuticals-16-00010-g002.jpg

Modifications of the Raytest SynChrom R&D synthesis module.

An external file that holds a picture, illustration, etc. Object name is pharmaceuticals-16-00010-g003.jpg

Configuration of the Raytest SynChrom R&D module for [18F]F-DOPA synthesis.

Table 3

Effect of the use of a disposable syringe on labeling efficiency.

VialSyringe
RCY (%)50%65%
20%70%
10%67%
40%72%
15%65%
TBAHCO3−, DMF, 10 mg precursor, 110 °C, n = 5

After the nucleophilic isotope exchange reaction, it was necessary to remove the polar solvent and unreacted reagents. For this purpose, various amounts and proportions of solvents were added to the reactor, and the reactor mixture was loaded onto the solid phase extraction (SPE) C18ec purification column.

During the first purification, 4 mL of water was used. This caused the precipitation of organic compounds, leading to blockage of the transfer capillaries and the purification column itself. The amount of 4 mL was due to the capacity of the first reactor. Modifications were made, and an overflow vial (Figure 2 and Figure 3) with 16 mL of water was added to be able to dilute the reactor mixture in more solvent. However, in this case, the transfer capillaries were also blocked.

In the following purification trials, a 4:1 mixture of the two solvents H2O/MeCN was applied: First, 4 mL of the mixture from the first reactor, and then an additional 16 mL from the overflow vial, as above. In this case, the transfer lines were not blocked.

Subsequently, radiolabeling was performed with 30 mg of the precursor in a disposable syringe, using an overflow vial and a 4:1 H2O/MeCN solvent mixture. A reduction in the flow rate of the reactor mixture to the column was observed during the post-labeling of the reaction mixture to the purification column. The formation of a precipitate was noted. The precipitate likely consisted of the unreacted precursor, insoluble in the solvent mixture used. This led to a low radiochemical yield of approximately 10% (Table 2).

Assessing the results obtained in previous studies on the synthesis of [18F]F-DOPA, it was proved in both the studies by Wagner et al. [16] and Pretze et al. [19] that the use of a smaller amount of precursor has a more favorable effect on the synthesis efficiency.

The use of lower amounts of the precursor exerts a favorable influence on the synthesis efficiency. It provides a better effect on the isolation of the intermediate product, the reduction of by-product formation, the specific activity of the product [16], and the substitution of 18F, using a combination of K222 in DMF instead of TBAHCO3- in DMSO [19].

In both of the above-mentioned studies, it was found that the amounts that do not exceed 10 mg of the precursor possess the best influence on the course of the synthesis: Wagner—5, 7 mg (precursor ABX 1335), Pretze—7 mg (precursor ABX 1336). It should be mentioned, however, that after prolonged storage, decomposition of the precursor occurs, which reduces the efficiency of substitution, and in this case, usage in larger amounts allows the efficiency to be maintained at an appropriate level [19].

2.3. Oxidation Using mCPBA

Different amounts of m-chloroperoxybenzoic acid (mCBPA) (10 mg, 9 mg, 8 mg, 7 mg, 6 mg, and 5 mg) were taken into account during the tests, and oxidation was carried out at 60 °C for 20 min.

During the experiments with the oxidant, a relationship was observed between the appropriately selected conditions of the oxidation step and the number of individual peaks in the chromatogram, after injecting the crude product into the semipreparative column. In the case of too low an amount of the oxidant used (5 mg, 6 mg), the appearance of the side compound peak was detected, following the specific peak of [18F]F-DOPA (Figure 4), whereas in the case of too high an amount of the oxidant (8 mg, 9 mg, 10 mg), the appearance of the side compound peak before the specific peak of [18F]F-DOPA was observed (Figure 5). In contrast, when the reaction conditions had been correctly selected (7 mg), no presence of side peaks was found (Figure 6 and Table 4).

An external file that holds a picture, illustration, etc. Object name is pharmaceuticals-16-00010-g004.jpg

Reaction with too low an amount of mCPBA.

An external file that holds a picture, illustration, etc. Object name is pharmaceuticals-16-00010-g005.jpg

Reaction with too high an amount of mCPBA.

An external file that holds a picture, illustration, etc. Object name is pharmaceuticals-16-00010-g006.jpg

Reaction with the correct amount of mCPBA.

Table 4

Comparison of oxidation conditions using mCPBA.

MethodTime (min)Temperature (°C)Amount of mCPBA (mg)SolventAmount of Precursor
(mg)
Sauvage [20]20 min60 °C-MeCN-
Martin [21]16 min55 °C-MeCN-
Pretze [19]20 min65 °C5 mgCH3Cl7 mg
Huang [22]9.5/5.5 min65/55 °C20 mg MeCN30 mg
This work20 min60 °C7 mgMeCN10 mg

The synthesis of [18F]F-DOPA remains very sensitive to the amount of oxidant, and to obtain good results, its concentration must be precisely adjusted to achieve the desired reaction conditions. The oxidative power of mCPBA decreases with time, which means that the mCPBA amount used in the synthesis must be constantly adjusted. The selection of appropriate oxidation conditions is also of great importance An appearance and high of the side-compound peaks in the semipreparative column chromatogram may indicate the oxidation condition changes. It provides the operator with the opportunity for a proper reaction.

2.4. Hydrolysis

The next stage in the radiosynthesis of [18F]F-DOPA was hydrolysis to deprotect groups. In this case, the absence of the imidazolidinone group allows the use of milder hydrolysis conditions compared to the synthesis using the ABX 1335 precursor [15]. As can be seen in Table 5, all compared methods of [18F]F-DOPA synthesis are based on the use of milder hydrolysis conditions. Additionally, ethanol (EtOH) was added in an amount of 3%, relative to the amount of 30% hydrochloric acid (HCl).

Table 5

Comparison of hydrolysis conditions with 30% HCl.

MethodTime (min)Temperature (°C)
Sauvage [20]-40 °C
Martin [21]20 min50 °C
Pretze [19]20 min65 °C
Huang [22]20 min50 °C
This work20 min60 °C

2.5. [18F]F-DOPA Crude Product Purification

Purification of the crude final product was carried out using the HPLC method by loading the mixture onto a Hamilton PRP 10 μm 250 × 10 mm semipreparative column. The mobile phase was water and the flow rate was 4 mL/min. The collection of the purified product from the semipreparative column took place by reversing the flow direction of the eluate exiting the column into the product reactor. The proper peak appeared after approximately 10 min (Figure 5). The yield of the total RCY synthesis was 8–10%.

As an alternative, a method using SPE columns was tested. In this case, the reaction mixture was purified using combined C18/HRP columns. The total yield increased to 13–15%. The method of purification using SPE columns was first proposed by Martin et al. [23]. Later, Pretze introduced modifications to this method, using a base to neutralize the acid after hydrolysis. In this work, the Pretze method was used as an alternative for semipreparative purification [19].

By applying the SPE column method, it was possible to eliminate operator error associated with starting the collection of the specific peak too late, which could have reduced the efficiency of the synthesis, or too early, which could have affected the final purity of the product.

3. Materials and Methods

3.1. General

Chemicals used for the synthesis and quality control of [18F]F-DOPA were purchased from Sigma Aldrich. The precursor for the synthesis of [18F]F-DOPA (ABX 1336), TBAHCO3−, and quality control standards was obtained from ABX Advanced Biochemical Compounds GmbH. SPE columns were purchased from Waters and Macherey-Nagel. All radio syntheses and their modifications were performed using the Raytest SynChrom R&D synthesis module.

3.2. Cyclotron Production of the Fluoride Isotope 18F

The SIEMENS Eclipse 11 MeV Cyclotron was used to produce the 18F isotope. The target material to produce 18F fluoride was water-enriched in the oxygen isotope [18O] H2O (2.4 mL) from Cambridge Isotope Laboratories (CIL water 18O, 97%). At the end of the bombardment (EOB, t = 0), the amount of the 18F fluoride isotope averaged 120 GBq. The 18F anion was transported in a 2.4 mL aqueous solution from the cyclotron target to the Raytest SynChrom R&D synthesis module through a Teflon capillary using argon as a pushing gas.

3.3. Automatic Radiosynthesis Using the Raytest Synchrom R&D Module

The 18F anion, free of impurities reducing its activity, was separated on the Preconditioned Sep-PAK Light QMA Cartridge with CO32− as the counter ions. The fluoride anion was recovered from the QMA column by elution with a 0.075M TBAHCO3− solution in MeCN, followed by double azeotropic distillation to remove residual water.

The precursor for the nucleophilic synthesis of [18F]F-DOPA (ABX 1336), (S)-3-(5-Formyl-4-methoxymethoxy-2-nitro-phenyl)-2-(trityl-amino)-propionic acid tert-butyl ester in DMF was added to the reaction vessel. The labeling temperature was maintained at 110 °C and the process lasted 10 min.

After the labeling was complete, the water-acetonitrile (H2O:MeCN) mixture was added to the reactor, and then the solution was loaded onto a Chromabond C18ec (octadecyl-modified silica, end-capped) purification column. DMF, the free isotope of fluoride [18F], 0.075 M TBAHCO3− and other contaminants formed during labeling were discharged into the waste. The intermediate was retained on the column, rinsed with 15 mL of H2O, and then eluted into a second reactor with 2 mL of MeCN.

In the next step, oxidation of the intermediate compound using mCBPA was carried out at 60 °C for 16 min. In order to remove the protecting groups from the intermediate compound, 1 mL of 30% HCl containing 3% EtOH was used. Hydrolysis was carried out for 20 min at a temperature of 60 °C. Then the crude [18F]F-DOPA was diluted with 5 mL of H2O. The last stage was the introduction of the solution on a semipreparative column, Hamilton PRP 10 μm 250 × 10 mm, and in order to purify and collect the final product [18F]F-DOPA, the eluent was H2O with a flow of 4 mL/min (Figure 3, Figure 7 and Table 6).

An external file that holds a picture, illustration, etc. Object name is pharmaceuticals-16-00010-g007.jpg

Schematic depiction of reaction conditions for [18F]F-DOPA synthesis using the ABX 1336 precursor.

Table 6

Details of module preparation for automated [18F]F-DOPA synthesis.

Vial/ComponentReagentVolume
SC10.075M TBAHCO3− in MeCN100 µL + 100 µL
SC2 syringeMeCN250 µL
SC3 syringePrecursor (ABX 1336) in DMF10 mg + 500 µL
SC4MeCN/H2O4 mL (4:1)
OVERFLOW VIALMeCN/H2O16 mL (4:1)
SC5H2O15 mL
SC6MeCN2 mL
SC7mCPBA in MeCN7 mg + 2 mL
SC8HCl (30%) + containing 3% EtOH1 mL + 30 µL
SC9H2O5 mL
Trap 1Conditioned QMAone
Trap 2Conditioned C18econe
Semipreparative HPLCHamilton PRP 10 μm 250 × 10 mm
H2O, flow 4 mL/min		-

3.4. Quality Control

General quality control of [18F]F-DOPA was performed according to Polish Pharmacopoeia 12th edition (based on the European Pharmacopoeia), the monograph Fluorodopae (18F) ab nucleophila substitutione solutio iniectabilis 04/2019: 2481, and European Pharmacopoeia 10th edition, the monograph Fluorodopae (18F) ab nucleophila substitutione solutio iniectabilis 04/2019: 2481. The estimation of residual solvents was performed according to Polish Pharmacopoeia 12th edition (based on the European Pharmacopoeia), chapter 5.4, and European Pharmacopoeia 10th edition chapter 5.4: Residual solvents.

According to specification and three Quality Control (QC) results (Table 7), QC of the produced [18F]F-DOPA included the appearance, potentiometric analysis of pH (4.0–5.5), examination of radionuclide identity (497–526 keV), approximate half-life (105–115 min), radiochemical purity (≥95% of total fluoride-18 radioactivity), enantiomeric purity (L-form ≥ 96% total fluoride-18 radioactivity), chemical purity (0.5 mg/V), residual solvent content (acetonitrile ≤ 0.82 mg/mL, ethanol ≤ 10 mg/mL, methanol ≤ 6 mg/mL, TBA residual (<0.26 mg/mL), analysis of bacterial endotoxin concentration (kinetic chromogenic method; <35 IU/mL), filter integrity test, and assessment of sterility.

Table 7

Specification and three QC results of [18F]F-DOPA using the Raytest SynChrom R&D module.

QC TestSpecification
(Acceptance Criteria)		QC Result
QC 1QC 2QC 3
AppearanceClear, colorless solutionComplyComplyComply
pH4.0–5.54.85.15.0
Radionuclidic identificationGamma photons have an energy of 497–526 keV514 keV516 keV512 keV
Half life105–115 min109.5109110
Radiochemical purity
(HPLC) 6-[18F]-DOPA		≥95% the total radioactivity99.6%97.6%99.4%
Radiochemical purity
(TLC) 6-[18F]-DOPA		≥95% the total radioactivity97.9%96.2%95.67%
Enantiomeric purity
L-form of 6-[18F]-DOPA		≥96% the total radioactivity97.4%98.9%98.1%
Chemical purity (HPLC)
All chemical impurities
Including total peak of
6-fluoro-L-DOPA		2.5 mg/5 mL
(0.5 mg/mL)		0.0107 mg/mL0.018 mg/mL0.4408 mg/mL
Residual TBA<1.3 mg/5 mL
(<0.26 mg/mL)		<0.26 mg/mL<0.26 mg/mL<0.26 mg/mL
Residual solvents:
Ethanol (GC)≤50 mg/5 mL
(≤10 mg/mL)		1.063 mg/mL0.004 mg/mL0.2706 mg/mL
Acetonitrile (GC)≤ 4.1 mg/5 mL
(≤ 0.82 mg/mL)		0.7854 mg/mL0.0023 mg/mL0.0029 mg/mL
Methanol (GC)≤30 mg/5 mL
(≤6 mg/mL)		0.8294 mg/mL0.0028 mg/mL0.0008 mg/mL
Bacterial endotoxins<175 EU/5 mL (<35 EU/mL)<0.250 EU/mL<0.250 EU/mL<0.250 EU/mL
Filter integrity test≥3 Bar4.0 Bar4.2 Bar4.0 Bar
Sterility *SterileComplyComplyComply

* The preparation may be released for use before completion of the test.

The identity and radionuclide purity were tested using the multi-channel analyzer (MUCHA) by Elysia-Raytest.

The radiochemical and chemical purity was verified with a high-performance liquid chromatograph Agilent HPLC 1200 connected in series with a Diode Array Detector (DAD), by means of a Synergi 4P Hydro-RP analytical column, 250 × 4.5 mm; Phenomenex, a flow of 1 mL/min, gradient elution, mobile phase: Aqueous acetic acid (0.1%): methanol 97:3 (v/v). To test the enantiomeric identity, an Agilent HPLC 1200 connected in series with a DAD detector (wavelength of 283 nm) was used, using a CHIRAL Daicel CROWNPAK CR (+) 5µ column, 4.0 × 150 mm, at a temperature of 15 °C with isocratic elution, a flow of 0.2 mL/min, and a mobile phase of a 0.02 M aqueous solution of chloric acid (VII).

The TBA residual was examined with an Agilent HPLC 1100 connected in series with the Ultraviolet UV detector (wavelength of 254 nm), using a NUCLEODURfi C18 Isis analytical column 100 × 4.6 mm 3µm, Macherey–Nagel, with a flow of 0.6 mL/min and a mobile phase of toluenesulfonic acid (0.95 g/L): acetonitrile 25:75 (v/v)

The radiochemical purity was also tested by TLC on silica gel plates (aluminum Silica Gel 60 F254 Merck), with a mobile phase of 0.4 M sulfuric (VI) acid: 0.005 M DTPA (1 mL:10 µL DTPA).

A GC gas chromatograph by Agilent with the application of a flame ionization detector (FID) and a Zebron ZB-WAXplus 30m × 0.53 mm × 1.00 µm column was used to test the content of residual solvents. The carrier gas was helium 6.0.

4. Conclusions

In conclusion, the nucleophilic method of [18F]F-DOPA synthesis was successfully performed using the ABX 1336 precursor and the Raytest SynChrom R&D module. The synthesis was performed for 120 min and the radiochemical yield was 15%, radiochemical purity was ≥97%, and enantiomeric purity was ≥96%.

The application of a smaller amount of the ABX 1336 precursor and the appropriate selection of the mCPBA oxidant in the Baeyer–Villiger oxidation had a better effect on the synthesis radiochemical yield.

The use of SPE purification of the crude product, as compared to purification on a semipreparative column, allowed the elimination of operator error resulting from collecting the specific peak too late, which could reduce the efficiency of the synthesis, or too early, which could affect the final purity of the product. However, the use of SPE purification does not provide the opportunity to observe the changing oxidation conditions and have the appropriate reaction.

It seems that, in order to avoid the above-described problems with the accumulation of impurities after synthesis, a better solution would be to use a module with replaceable disposable radiosynthesis cassettes or a cleaning system immediately after synthesis.

Funding Statement

This research was funded by Nicolaus Copernicus University in Torun of the IDUB UMK program.

Author Contributions

Conceptualization, P.W.; methodology, P.W. and J.C.; software: P.W. and D.M.; validation: P.W., D.M., M.C. and J.C.; formal analysis: P.W. and S.S.; investigation: P.W. and J.C.; resources: P.W., B.M. and S.S.; data curation: P.W., J.C. and M.C.; writing—original draft preparation: P.W., J.C., M.W. and M.C.; writing—review and editing: P.W., J.C., M.W. and M.C.; visualization: P.W. and M.W.; supervision, P.W., S.S. and B.M.; project administration: P.W. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article.

Conflicts of Interest

The authors declare no conflict of interest.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

1. Garnett E.S., Firnau G., Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature. 1983;305:137–138. 10.1038/305137a0. [Abstract] [CrossRef] [Google Scholar]
2. Fischman A.J. Role of [18F]-dopa-PET imaging in assessing movement disorders. Radiol. Clin. N. Am. 2005;43:93–106. 10.1016/j.rcl.2004.08.002. [Abstract] [CrossRef] [Google Scholar]
3. Darcourt J., Schiazza A., Sapin N., Dufour M., Ouvrier M.J., Benisvy D., Fontana X., Koulibaly P.M. 18F-FDOPA PET for the diagnosis of parkinsonian syndromes. Q. J. Nucl. Med. Mol. Imaging. 2014;58:355–365. [Abstract] [Google Scholar]
4. Groves A.M., Win T., Haim S.B., Ell P.J. Non-[18F]FDG PET in clinical oncology. Lancet Oncol. 2007;8:822–830. 10.1016/S1470-2045(07)70274-7. [Abstract] [CrossRef] [Google Scholar]
5. Seibyl J.P., Chen W., Silverman D.H. 3,4-Dihydroxy-6-[18F]fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors. Semin. Nucl. Med. 2007;37:440–450. 10.1053/j.semnuclmed.2007.08.002. [Abstract] [CrossRef] [Google Scholar]
6. Jager P.L., Chirakal R., Marriott C.J., Brouwers A.H., Koopmans K.P., Gulenchyn K.Y. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: Basic aspects and emerging clinical applications. J. Nucl. Med. 2008;49:573–586. 10.2967/jnumed.107.045708. [Abstract] [CrossRef] [Google Scholar]
7. O'Brien S.R., States L.J., Zhuang H. Neuroblastoma Shown on 18F-DOPA PET/CT Performed to Evaluate Congenital Hyperinsulinism. Clin. Nucl. Med. 2021;46:927–928. 10.1097/RLU.0000000000003689. [Abstract] [CrossRef] [Google Scholar]
8. Piccardo A., Lopci E. Potential role of 18F-DOPA PET in neuroblastoma. Clin. Transl. Imaging. 2016;4:79–86. 10.1007/s40336-016-0162-2. [CrossRef] [Google Scholar]
9. Fluorodopa (18F) (prepared by electrophilic substitution) injection. Eur. Pharmacopoeia. 2008;6:990–992. [Google Scholar]
10. Namavari M., Bishop A., Satyamurthy N., Vida G., Barrio J.R. Regioselective radiofluorodestannylation with [18F]F2 and [18F]CH3COOF: A high yield synthesis of [18F]fluoro-L-dopa. Appl. Radiat. Isot. 1992;43:989–996. 10.1016/0883-2889(92)90217-3. [Abstract] [CrossRef] [Google Scholar]
11. Luxen A., Guillaume M., Melega W.P., Pike V.W., Solin O., Wagner R. Production of 6-[18F]fluoro-L-dopa and its metabolism in vivo—A critical review. Int. J. Radiat. Appl. Instrum. Part B Nucl. Med. Biol. 1992;19:149–158. 10.1016/0883-2897(92)90002-G. [Abstract] [CrossRef] [Google Scholar]
12. Tredwell M., Gouverneur V. 18F Labeling of Arenes. Angew. Chem. Int. Ed. 2012;51:11426–11437. 10.1002/anie.201204687. [Abstract] [CrossRef] [Google Scholar]
13. Hess E., Blessing G., Coenen H.H., Qaim S. Improved target system for production of high purity [18F] fluorine via the 18O(p,n)18F reaction. Appl. Radiat. Isot. 2000;52:1431–1440. 10.1016/S0969-8043(99)00248-1. [Abstract] [CrossRef] [Google Scholar]
14. Kuik W.J., Kema I.P., Brouwers A.H., Zijlma R., Neumann K.D., Dierckx R.A.J.O., DiMagno S.G., Elsinga P.H. In Vivo Biodistribution of No-Carrier-Added 6-18F-Fluoro-3,4-Dihydroxy-L-Phenylalanine (18F-DOPA), Produced by a New Nucleophilic Substitution Approach, Compared with Carrier-Added 18F-DOPA, Prepared by Conventional Electrophilic Substitution. J. Nucl. Med. 2014;56:106–112. 10.2967/jnumed.114.145730. [Abstract] [CrossRef] [Google Scholar]
15. Libert L.C., Franci X., Plenevaux A.R., Ooi T., Maruoka K., Luxen A.J., Lemaire C.F. Production at the Curie Level of No-Carrier-Added 6-18F-Fluoro-l-Dopa. J. Nucl. Med. 2013;54:1154–1161. 10.2967/jnumed.112.112284. [Abstract] [CrossRef] [Google Scholar]
16. Wagner F.M., Ermert J., Coenen H.H. Three-Step, “One-Pot” Radiosynthesis of 6-Fluoro-3,4-Dihydroxy-L-Phenylalanine by Isotopic Exchange. J. Nucl. Med. 2009;50:1724–1729. 10.2967/jnumed.109.063297. [Abstract] [CrossRef] [Google Scholar]
17. Pretze M., Wängler C., Wängler B. 6-[18F]Fluoro-L-DOPA: A Well-Established Neurotracer with Expanding Application Spectrum and Strongly Improved Radiosyntheses. BioMed Res. Int. 2014;2014:674063. 10.1155/2014/674063. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
18. Mele’an J.C., Ermert J., Coenen H.H. Enantiospecific synthesis of 2-[18F]fluoro-L-phenylalanine and 2-[18F]fluoro-L-tyrosine by isotopic exchange. Org. Biomol. Chem. 2011;9:765–769. 10.1039/C0OB00440E. [Abstract] [CrossRef] [Google Scholar]
19. Pretze M., Franck D., Kunkel F., Foßhag E., Wängler C., Wängler B. Evaluation of two nucleophilic syntheses routes for the automated synthesis of 6-[18F]fluoro-l-DOPA. Nucl. Med. Biol. 2017;45:35–42. 10.1016/j.nucmedbio.2016.10.007. [Abstract] [CrossRef] [Google Scholar]
20. Sauvage C., Lazarova N., Mueller M. 18F-L-FDOPA Automated Production via the Nucleophilic Route. J. Nucl. Med. 2015 May 20;56((Suppl. 3)):1011. [Abstract] [Google Scholar]
21. Martin R., Baumgart D., Huebner S., Juettler S., Saul S., Clausnitzer A., Mollitor J., Smits R., Hoepping A., Mueller M. Automated nucleophilic one-pot synthesis of F-18-L-DOPA with high specific activity using the GE TRACERlab MXFDG. J. Label. Compd. Radiopharm. 2013;56:S126. [Google Scholar]
22. Huang Y.Y., Poniger S., Tsai C.L., Tochon-Danguy H.J., Ackermann U., Yen R.F. Three-step two-pot automated production of NCA [18F]FDOPA with FlexLab module. Appl. Radiat. Isot. 2020;158:108871. 10.1016/j.apradiso.2019.108871. [Abstract] [CrossRef] [Google Scholar]
23. Martin R., Baumgart D., Huebner S., Juettler S., Saul S., Clausnitzer A., Mollitor J., Smits R., Hoepping A., Mueller M. First SPE method for routine production of nucleophilic L-[18F]FDOPA. J. Label Compd. Radiopharm. 2013;56:S126. [Google Scholar]
Articles from Pharmaceuticals are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

Full text links 

Read article at publisher's site: https://doi.org/10.3390/ph16010010

Read article for free, from open access legal sources, via Unpaywall: https://www.mdpi.com/1424-8247/16/1/10/pdf?version=1671693593Unpaywall

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

Nicolaus Copernicus University (1)

Nicolaus Copernicus University in Torun of the IDUB UMK program